Godavari Biorefineries Ltd

Dated: August 05, 2026

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

Script Symbol: GODAVARIB

The Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street
Mumbai-400001

Script Code:544279

Dear Sir / Madam,

Sub: Submission of Press Release on unaudited financial results for the Quarter Ended June 30, 2026

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release being issued by the Company with respect to the Unaudited Financial Results for the quarter ended June 30, 2026, as approved by the Board of Directors at its meeting held today.

The aforesaid Press Release is also being made available on the website of the Company.

Kindly take the same on record

Thanking you,
Yours faithfully

For Godavari Biorefineries Limited

MANOJ JAIN
Digitally signed by MANOJ JAIN
Date: 2026.08.05 22:37:57 +05'30'

Manoj Jain
Company Secretary & Compliance Officer
Membership No. F-7998

Regd. Office : Somaiya Bhavan, 45/47, Mahatma Gandhi Road, Fort, Mumbai - 400 001 INDIA.
Tel : (91-22) 2204 8272 / 6170 2100 Fax : (91-22) 2204 7297
Email ID : investors@somaiya.com www.godavaribiorefineries.com
CIN:L67120MH1956PLC009707

Somaiya GROUP

Godavari Biorefineries Ltd.

Godavari Biorefineries Limited Reports Q1 FY27 Results

Resilient revenue growth amid industry headwinds

Mumbai, 05th August 2026 – Godavari Biorefineries Ltd., one of the largest producers of ethanol and a pioneer in manufacturing bio-based specialty chemicals in India, announced its Financial Results for the quarter ended on **June 30, 2026.**

Q1 FY27 Key Snapshot

Bio-based Chemicals	Financial Strength	Ethanol	Drug Discovery
53%	**₹13.9 Cr**	**200 KLPD**	**Japanese Patent**
EBITDA Growth YoY	Finance costs	Grain-based distillery commissioned	Granted for Novel Anti-cancer Molecule
11.4%	**▼9.0% YoY**	**800 KLPD**	**CDSCO Application**
EBITDA Margin vs 8.9% in Q1 FY26	(₹15.3 crore in Q1 FY26)	Total Capacity	Filed for Preliminary Efficacy Trials for our lead novel anti-cancer molecule

Q1 FY27 Financial Performance *(Consolidated)*

TOTAL INCOME	EBITDA*	PAT
Rs. 559.9 Cr	Rs. 2.6 Cr	Rs. (19.3) Cr

Particulars (Rs. Cr)	Q1 FY27	Q1 FY26	Q4 FY26	FY26
Total Income	559.9	534.0	570.0	2,000.2
EBITDA^	2.6	6.5	92.1	139.3
PAT	(19.3)	(16.0)	52.9	3.5

** EBIDTA Includes Other Income*

Segment Revenue Mix

Revenue from Operations
Rs. 557.9 Crores



Revenue from Operations
Rs. 533.2 Crores



Sugar & Cogeneration | Bio-Based Chemicals | Ethanol | Unallocated

Commenting on the Results, Shri Samir Somaiya, CMD said,

"Q1 FY27 marked an important quarter in strengthening Godavari Biorefineries' integrated platform through strategic execution and operational milestones. During the quarter, we successfully commissioned our 200 KLPD grain-based distillery at Sameerwadi, increasing our total ethanol capacity to 800 KLPD and significantly enhancing our feedstock flexibility. This investment strengthens our ability to optimize operations across varying market conditions while creating a more resilient and future-ready ethanol business.

Our Bio-based Chemicals business delivered another strong quarter, with robust revenue growth, healthy margin expansion and improved profitability, reflecting the benefits of our debottlenecking initiatives and continued focus on higher-value specialty products. During the quarter, we also secured an Indian patent for a cost-effective process to manufacture branched alcohols, reflecting our continued focus on developing efficient and differentiated technologies.

Further advancing our innovation pipeline, we filed with the CDSCO to initiate preliminary efficacy trials for our lead anti-cancer molecule targeting Triple Negative Breast Cancer, with trials expected to commence from Q3 FY27, subject to regulatory approvals. This marks a significant milestone in translating our R&D efforts into potential clinical applications.

As we look ahead, our strategic priorities remain centered on expanding our high-value Bio-based Chemicals portfolio, strengthening strategic partnerships and commercialising innovation-led products. We are equally focused on enhancing ethanol fungibility to capitalise on India's evolving biofuel landscape, alongside sustained efforts in R&D and product innovation. These initiatives, supported by our integrated bio-refinery platform, position us well to deliver sustainable long-term growth and value creation."

About Godavari Biorefineries Ltd

Godavari Biorefineries Ltd is one of the largest producers of ethanol and a pioneer in manufacturing bio-based specialty chemicals in India. It's diversified product portfolio comprises bio-based chemicals, sugar, rectified spirits, ethanol, other grades of alcohol and power. It is the only company in India to have such a vast portfolio of bio-based products.

Company	Investor Relations: MUFG Intime India Pvt. Ltd.
Name: Mr. Ashish Sinha – AGM IR & Finance	Name: Ms. Prachi Ambre / Mr. Irfan Raeen
Email: investorrelations@somaiya.com	Email: prachi.ambre@in.mpms.mufg.com / irfan.raeen@in.mpms.mufg.com
CIN: L67120MH1956PLC009707	Meeting Request Link
https://godavaribiorefineries.com/	Website: https://in.mpms.mufg.com/

Safe Harbor

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. Past performance also should not be simply extrapolated into the future. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.